Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sunesis presents encouraging Phase II data for cancer drug
In this trial, single agent SNS-595 has demonstrated disease control (defined as stable disease, partial response or complete response) in 31 of 35 patients evaluable for best response
In this trial, single agent SNS-595 has demonstrated disease control (defined as stable disease, partial response or complete response) in 31 of 35 patients evaluable for best response
This IV Busulfex is an oncology product marketed and sold in the US and Canada, and through distributors in a number of other countries. Otsuka will oversee the
The company has said that Liquadd will be launched during the second quarter of 2008. Frank Greico, CEO of Auriga, said: “This new product further solidifies company’s commitment
Avexa plans to use Monogram’s assays across its virology portfolio, including the Phase III program for its lead compound, apricitabine, an anti-HIV drug. Avexa also plans to use
The study, which is being conducted at over five sites in Australia, will enroll up to 24 patients who will receive either KB002 or placebo. Endpoints for the
Financial Highlights Operating profit increased 17.9% to $13.2 million (2008: $11.2 million) EBITDA increased 13.9% to $15.6 million (2008: $13.7 million) and EBITDA margin increased to 29.7% (2008:
The decision is followed by the meeting with representatives of the FDA to discuss the previously announced failed results of company’s pivotal Phase III clinical trial of MyVax.
This patent further strengthens the company’s position in using its Gut Endocrine cell Modification System (GEMS) gene transfer technology to induce gut K-cells to produce insulin in a
The company also said that the vaccine has shown 100% efficacy in preventing precancerous lesions due to cancer-causing virus types 16 and 18 and also provided substantial protection
The trial (study 06CCL3-001) is a multi-centre, randomized, double-blind, parallel-arm study that will compare the efficacy and safety of company’s twice-daily tramadol-acetaminophen combination product. The study, which is